



PHARMACY UPDATE

April 1, 2017

UPDATE #17-005

Page 1 of 5

This update applies to:

All retail pharmacies

States:

- Oregon
- Washington

Line of business:

- Commercial

PHARMACY INQUIRIES ONLY:

**Claims Processing/
Technical Support**

**Caremark
Claims Processing**

Commercial Pharmacy
Help Desk:
1-800-600-0180

*For optimal service,
this telephone number
is for pharmacy use
only.

MEMBER INQUIRIES:

Refer all member
inquiries to the
appropriate Customer
Service phone number
listed on their Health
Net ID card.

Second Quarter 2017 Drug List Changes

The following update includes changes to Commercial drug lists. Changes apply to all Commercial drug lists, unless stated otherwise.

- The Essential Rx Drug List (EDL) is used for Large Groups, Small Groups and Individual Plans.
- The Aon Active Health Exchange Drug List (ADL) is used by groups that purchased plans through the Aon Active Health Exchange.

View the most current version of our drug lists on www.healthnet.com.

QUESTIONS

For questions regarding the information in this update, please contact the Health Net Pharmacy Department at 1-888-802-7001, Option 1, and then Option 4.

Pharmacy Drug List Changes

Second Quarter 2017 - COMMERCIAL PRODUCTS

Changes apply to all formularies unless a specific formulary is noted.

AC = Anti-cancer

ADL = AonActive Drug List

EDL = Essential Rx Drug List

NF = Non Formulary

SP = Specialty

Step Therapy = Prior authorization is required if Step Therapy is not met.

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
Tier 1 Additions and Changes			
Aggrenox®	aspirin-dipyridamole SR capsule	Platelet Inhibitor Indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.	New generic available at Tier 1
Azilect®	rasagiline mesylate tablet	Selective MAO-B Inhibitor Treatment of Parkinson's disease.	New generic available at Tier 1
Focalin XR® 25 mg and 35 mg	dexmethylphenidate SR 24 hour capsule	Adrenergic Agonist Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.	New generic available at Tier 1
Kaletra® 400-100 mg/5ml solution	lopinavir-ritonavir 400-100 mg/5ml solution	Anti-Retroviral Protease Inhibitor Treatment of Human Immunodeficiency Virus (HIV).	New generic available at Tier 1
Pristiq®	desvenlafaxine succinate SR tablet	Serotonin-Norepinephrine Reuptake Inhibitor Treatment of major depression.	New generic available at Tier 1
Tier 2 Additions and Changes			
EpiPen® 2-PAK	epinephrine 0.3mg/0.3ml auto-injector solution for injection	Adrenergic Agonist Treatment of an emergency anaphylactic episode.	Tier 2 Prior authorization added Step-therapy required (Try epinephrine auto-injector)
EpiPen JR® 2-PAK	epinephrine 0.15mg/0.15ml auto-injector solution for injection	Adrenergic Agonist Treatment of an emergency anaphylactic episode.	Tier 2 Prior authorization added Step-therapy required (Try epinephrine auto-injector)
Invokamet® XR	canagliflozin-metformin SR 24-hour tablet	Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Treatment of type 2	Tier 2

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
		diabetes mellitus.	
Tier 3 Additions and Changes			
Aubagio®	teriflunomide tablet	Pyrimidine Synthesis Inhibitor Treatment of relapsing forms of multiple sclerosis.	Changed from Tier SP to Tier 3 Prior authorization required
Bevespi Aerosphere®	formoterol fumarate/glycopyrrolate inhalation aerosol	Long-acting Beta 2-Adrenergic Agonist/Anticholinergic Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).	Tier 3 Limited to 1 inhaler per month
Bromsite™	bromfenac sodium ophthalmic solution 0.075%	Ophthalmic Nonsteroidal Anti-inflammatory Drug (NSAID) Treatment of postoperative ocular inflammation and ocular pain following cataract surgery.	Tier 3
Cambia®	diclofenac potassium 50 mg powder for oral solution	Ophthalmic Nonsteroidal Anti-inflammatory Drug (NSAID) Acute treatment of migraine attacks with or without aura in adults 18 years of age or older.	Tier 3 Limited to 9 per month Added prior authorization Step therapy required (Try generic Maxalt)
Gilenya™	fingolimod capsule	Sphingosine 1-Phosphate Receptor Modulator Treatment of relapsing forms of multiple sclerosis, and to reduce the frequency of clinical exacerbations and to delay physical disability.	Changed from Tier SP to Tier 3 Prior authorization required
GoNitro™	nitroglycerin sublingual powder packet 400 mcg	Nitrate Indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.	Tier 3 Prior authorization required Step therapy required (Try generic Nitrostat)
Qbrelis™	lisinopril oral solution 1 mg/ml	Angiotensin-Converting Enzyme (ACE) Inhibitor Treatment of hypertension in adults and pediatric patients 6 years of age and older.	Tier 3 Limited to 1 bottle per month
Royaldee®	calcifediol extended-release capsule	Vitamin D Analog Treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-	Tier 3 Prior authorization required Step-therapy required (Try ergocalciferol)

Brand Name	Generic Name	Therapeutic Category & Indication	Comments
		hydroxyvitamin D levels less than 30 ng/ml	
Taytulla™	norethindrone acetate 1 mg - ethinyl estradiol 20 mcg - ferrous fumarate capsule	Combination Contraceptive For the prevention of pregnancy.	Tier 3* (OR EDL) Tier PV (ADL and WA EDL) Prior authorization required Step-therapy required (Try generic Loestrin)
Tecfidera®	dimethyl fumarate capsule	Neurological Agent Treatment of relapsing forms of multiple sclerosis.	Changed from Tier SP to Tier 3 Prior authorization required
Xiidra®	lifitegrast 5% ophthalmic solution	Lymphocyte Function Associated Antigen-1 Antagonist Treatment of the signs and symptoms of dry eye disease.	Tier 3 Prior authorization required Step-therapy required (Try OTC and topical corticosteroids or Restasis)
Zurampic®	lesinurad tablet	Anti-gout Agent Treatment of hyperuricemia associated with gout.	Tier 3 Prior authorization required
Specialty Tier and Other Additions and Changes			
Inflectra®	infliximab-dyyb solution for intravenous infusion	Tumor Necrosis Factor (TNF) Alpha Inhibitor Treatment of ulcerative colitis, pediatric and adult Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.	SP (EDL) Prior authorization required
Relistor®	methylnaltrexone bromide 150 mg tablet	Peripheral Mu-opioid Receptor Antagonist Treatment of opioid-induced constipation in adults with chronic non-cancer pain.	SP (EDL) Tier 3 (ADL) Prior authorization required
Vemlidy®	tenofovir alafenamide fumarate tablet	Anti-Retroviral Nucleotide Reverse Transcriptase Inhibitor Treatment of chronic Hepatitis B	SP (EDL) Tier 3 (ADL) Prior authorization required Step-therapy required (Try Viread or Baraclude)
Zinbryta®	daclizumab syringe 150 mg/ml	Interleukin-2 Inhibitor Treatment of relapsing forms of multiple sclerosis.	SP (EDL) Tier 3 (ADL) Prior authorization required

- Changes listed in the table apply to EDL and ADL unless a specific formulary is noted.
- Tier 1*, Tier 2*, Tier 3*, PV - These preventive medications are covered at \$0 cost share if you have a Preventive Pharmacy benefit.

UPDATED SAFETY INFORMATION FOR CONCOMITANT USE OF MEDICATIONS

In August 2016, the Food and Drug Administration (FDA) announced new safety changes to opioid and benzodiazepine labeling and patient Medication Guides. Opioids are powerful prescription medications used to treat pain and cough. Benzodiazepines are a class of medications that treat anxiety, insomnia, and seizures. These changes include a new *Boxed Warning* to the drug labeling of prescription opioid pain and prescription opioid cough medicines, and benzodiazepines. The FDA found that the combined use of opioid medications with benzodiazepines or other drugs

that depress the central nervous system (CNS) has resulted in serious side effects, including slowed or difficult breathing, sedation, coma, and death.

Health care professionals should limit prescribing opioid pain medication with benzodiazepines or other CNS depressants to patients for whom alternative options are not available. If these medications are prescribed together, duration and dosages should be limited to the minimum possible to achieve the desired clinical effect. Avoid prescribing prescription opioid cough medicines for patients taking benzodiazepines or other CNS depressants. In addition, health care professionals should warn patients and caregivers about the risks of slowed or difficult breathing, in addition to other associated signs and symptoms.

WARNING AGAINST CONCOMITANT USE OF TRAMADOL AND SEROTONERGIC DRUGS

Contained within the FDA labeling of tramadol products is information warning of the possible risk of serotonin syndrome. The development of potentially life-threatening serotonin syndrome may occur with the use of tramadol products with concomitant use of serotonergic drugs including but not limited to SSRIs (e.g. escitalopram, fluoxetine) and SNRIs (e.g. duloxetine, venlafaxine). These drugs can impair metabolism of serotonin or impair metabolism of tramadol. This may occur within the recommended dose.

Health care professionals should monitor patients whom are receiving tramadol with other serotonergic drugs, and warn patients and caregivers on the symptoms of serotonin syndrome. Serotonin syndrome may include mental-status changes (e.g., agitation, confusion, hallucinations, coma), autonomic instability (e.g., rapid heart rate, high blood pressure, hyperthermia), neuromuscular aberrations (e.g., muscle rigidity, loss of muscle coordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).